123 related articles for article (PubMed ID: 37537715)
1. A Trojan Horse Delivery Vehicle Carrying siRNA Nanotherapeutics with Multiple Tumor Microenvironment Responsiveness Elicits Robust Antitumor Immune Responses In Situ via a "Self-Synergistic" Approach.
Fang Y; Chen S; Zhang M; Lin X; Jin X; Zhang M; Liu Y; Wang Y; Shi K
Adv Healthc Mater; 2023 Nov; 12(28):e2301401. PubMed ID: 37537715
[TBL] [Abstract][Full Text] [Related]
2. Tailoring biomimetic dual-redox-responsive nanoplexes for enhanced RNAi-synergized photodynamic cancer immunotherapy.
Fang Y; Chen S; Zhang M; Lin X; Jin X; Zhang M; Liu Y; Wang Y; Shi K
Acta Biomater; 2023 Feb; ():. PubMed ID: 36792046
[TBL] [Abstract][Full Text] [Related]
3. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
[TBL] [Abstract][Full Text] [Related]
4. A tumor microenvironment responsive biodegradable CaCO
Liu Y; Pan Y; Cao W; Xia F; Liu B; Niu J; Alfranca G; Sun X; Ma L; de la Fuente JM; Song J; Ni J; Cui D
Theranostics; 2019; 9(23):6867-6884. PubMed ID: 31660074
[TBL] [Abstract][Full Text] [Related]
5. A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy.
Ding M; Fan Y; Lv Y; Liu J; Yu N; Kong D; Sun H; Li J
Acta Biomater; 2022 Sep; 149():334-346. PubMed ID: 35779775
[TBL] [Abstract][Full Text] [Related]
6. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
[TBL] [Abstract][Full Text] [Related]
7. Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma.
Wang C; Shi X; Song H; Zhang C; Wang X; Huang P; Dong A; Zhang Y; Kong D; Wang W
Biomaterials; 2021 Jan; 268():120579. PubMed ID: 33278683
[TBL] [Abstract][Full Text] [Related]
8. Integrated Nanorod-Mediated PD-L1 Downregulation in Combination with Oxidative-Stress Immunogene Therapy against Cancer.
Wu S; Zhang J; Pan J; Bai S; Wang Z; Chen Y; Xu D; An Y; Liu C; Chu C; Dai Q; Jiang L; Lu Z; Liu G
Adv Healthc Mater; 2023 Jul; 12(17):e2300110. PubMed ID: 36773310
[TBL] [Abstract][Full Text] [Related]
9. Photo-responsive hollow silica nanoparticles for light-triggered genetic and photodynamic synergistic therapy.
Lin X; Wu M; Li M; Cai Z; Sun H; Tan X; Li J; Zeng Y; Liu X; Liu J
Acta Biomater; 2018 Aug; 76():178-192. PubMed ID: 30078423
[TBL] [Abstract][Full Text] [Related]
10. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
Wan WJ; Qu CX; Zhou YJ; Zhang L; Chen MT; Liu Y; You BG; Li F; Wang DD; Zhang XN
Int J Pharm; 2019 Jul; 566():731-744. PubMed ID: 31212055
[TBL] [Abstract][Full Text] [Related]
12. Self-Delivered and Self-Monitored Chemo-Photodynamic Nanoparticles with Light-Triggered Synergistic Antitumor Therapies by Downregulation of HIF-1α and Depletion of GSH.
Zhang Z; Wang R; Huang X; Luo R; Xue J; Gao J; Liu W; Liu F; Feng F; Qu W
ACS Appl Mater Interfaces; 2020 Feb; 12(5):5680-5694. PubMed ID: 31944660
[TBL] [Abstract][Full Text] [Related]
13. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
14. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma.
Xu J; Zheng Q; Cheng X; Hu S; Zhang C; Zhou X; Sun P; Wang W; Su Z; Zou T; Song Z; Xia Y; Yi X; Gao Y
J Nanobiotechnology; 2021 Oct; 19(1):355. PubMed ID: 34717654
[TBL] [Abstract][Full Text] [Related]
15. ROS-Activatable siRNA-Engineered Polyplex for NIR-Triggered Synergistic Cancer Treatment.
Zhang M; Weng Y; Cao Z; Guo S; Hu B; Lu M; Guo W; Yang T; Li C; Yang X; Huang Y
ACS Appl Mater Interfaces; 2020 Jul; 12(29):32289-32300. PubMed ID: 32584027
[TBL] [Abstract][Full Text] [Related]
16. Metabolic reprogramming mediated PD-L1 depression and hypoxia reversion to reactivate tumor therapy.
Zhou Z; Liu Y; Song W; Jiang X; Deng Z; Xiong W; Shen J
J Control Release; 2022 Dec; 352():793-812. PubMed ID: 36343761
[TBL] [Abstract][Full Text] [Related]
17. Red-light-triggered self-destructive mesoporous silica nanoparticles for cascade-amplifying chemo-photodynamic therapy favoring antitumor immune responses.
Yang Y; Chen F; Xu N; Yao Q; Wang R; Xie X; Zhang F; He Y; Shao D; Dong WF; Fan J; Sun W; Peng X
Biomaterials; 2022 Feb; 281():121368. PubMed ID: 35030436
[TBL] [Abstract][Full Text] [Related]
18. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
[TBL] [Abstract][Full Text] [Related]
19. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
